[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-333817-105":59,"doc-detail-333817-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","pharmacomicrobiomics-in-precision-cancer-therapy-bench-to-bedside","Pharmacomicrobiomics in precision cancer therapy - bench to bedside","","The review examines pharmacomicrobiomics as a rapidly expanding discipline that links microbiome composition and activity with cancer biology and treatment response. It analyzes molecular mechanisms connecting distinct microbial communities to antitumor immunity and to outcomes across chemotherapy, immunotherapy, and radiation therapy. The work also evaluates obstacles to microbiome-based interventions, emphasizing the need for standardization, validation, and clinical translation, while synthesizing evidence to support improved decision-making in precision oncology.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pharmacomicrobiomics-in-precision-cancer-therapy-bench-to-bedside/333817/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pharmacomicrobiomics-in-precision-cancer-therapy-bench-to-bedside/333817.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the core goal of pharmacomicrobiomics in precision cancer therapy?","Question",{"text":112,"@type":113},"It investigates how individual microbiomes influence drug metabolism, efficacy, and toxicity, thereby shaping treatment response in cancer patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the microbiome affect different cancer treatments?",{"text":117,"@type":113},"The review describes microbiome roles in modulating antitumor immunity and influencing response to chemotherapy, immunotherapy, and radiation therapy, including therapy resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"Why can’t pharmacogenomic biomarkers fully explain individual differences in drug response?",{"text":121,"@type":113},"Clinical evidence indicates pharmacogenomic markers only partially account for inter-individual variation, motivating additional biomarker research beyond genetics.",{"name":123,"@type":110,"acceptedAnswer":124},"What barriers limit microbiome-based interventions in cancer therapy?",{"text":125,"@type":113},"Major challenges include standardization of methods, validation of findings, and effective clinical translation from research into routine practice.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},333817,1790109588,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":4},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Review  \nPUBLISHED 09 September 2024 DOI 10.3389/fimmu.2024.1428420  \nOPEN ACCESS  \nEDITED BY  \nMatija Rijavec,  \nUniversity Clinic of Pulmonary and Allergic Diseases Golnik, Slovenia  \nREVIEWED BY Urska Janzic,  \nUniversity Clinic of Pulmonary and Allergic Diseases Golnik, Slovenia  \nYuting Ke,  \nMassachusetts Institute of Technology, United States  \n*CORRESPONDENCE Phung Thanh Huong  \n [huongpt@hup.edu.vn](huongpt@hup.edu.vn)  \n†These authors have contributed equally to this work and share first authorship  \nRECEIVED 08 May 2024  \nACCEPTED 19 August 2024  \nPUBLISHED 09 September 2024  \nCITATION  \nLe Ngoc K, Pham TTH, Nguyen TK and Huong PT (2024) Pharmacomicrobiomics in precision cancer therapy: bench to bedside.  \nFront. Immunol. 15:1428420 .  \ndoi: 10.3389/fimmu.2024.1428420  \nCOPYRIGHT  \n© 2024 Le Ngoc, Pham, Nguyen and Huong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPharmacomicrobiomics in precision cancer therapy:  \nbench to bedside  \nKhanh Le Ngoc †, Tran Thu Ha Pham †, Tiep Khac Nguyen and Phung Thanh Huong*  \nFaculty of Biotechnology, Hanoi University of Pharmacy, Hanoi, Vietnam  \nThe burgeoning field of pharmacomicrobiomics offers promising insights into the intricate interplay between the microbiome and cancer, shaping responses to diverse treatment modalities. This review aims to analyze the molecular mechanisms underlying interactions between distinct microbiota types and cancer, as well as their influence on treatment outcomes. We explore how the microbiome impacts antitumor immunity, and response to chemotherapy, immunotherapy, and radiation therapy, unveiling its multifaceted roles in cancer progression and therapy resistance. Moreover, we discuss the challenges hindering the development of microbiome-based interventions in cancer therapy, including standardization, validation, and clinical translation. By synthesizing clinical evidence, we underscore the transformative potential of harnessing pharmacomicrobiomics in guiding cancer treatment decisions, paving the way for improved patient outcomes in clinical practice.  \nKEYWORDS  \ncancer therapy, microbiota, microbiome intervention, pharmacomicrobiome, precision medicine  \n1 Introduction  \nPrecision medicine, or personalized therapy, is a rapidly evolving trend in modern healthcare, tailoring treatment to individual patients by selecting the right drug, at the right dose and at the right time based on their specific cellular, molecular, and genetic characteristics. This approach optimizes treatment effectiveness while minimizing the risk of adverse drug reactions (ADRs) . Among therapeutic fields, cancer treatment has seen particularly swift advancements in precision medicine due to its typical characteristics such as the highly heterogeneous nature of tumors, substantial variability in drug response among individuals, and the significant side effects associated with cancer therapies (1) . Additionally, the high costs of treatment and the invaluable cost of life opportunities necessitate precise treatment protocols without room for trial and error. Biomarkers used  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nto predict treatment response and disease prognosis not only aid in selecting appropriate drugs for patients but also drive innovation in drug development, reducing time and costs for clinical trials and substantially increasing success rates (2) .  \nTo date, the most extensively utilized biomarker in personalized cancer therapy is the somatic mutations found in tumors. These mutations assist in identifying patients who are likely to","cbCailrFkp8BaR85","https://ap.wps.com/l/cbCailrFkp8BaR85","pdf",2679032,26,"English","# Introduction\n## Precision medicine and cancer therapy\n## Biomarkers and pharmacogenomics\n## Emergence and scope of pharmacomicrobiomics","[{\"question\":\"What is the core goal of pharmacomicrobiomics in precision cancer therapy?\",\"answer\":\"It investigates how individual microbiomes influence drug metabolism, efficacy, and toxicity, thereby shaping treatment response in cancer patients.\"},{\"question\":\"How does the microbiome affect different cancer treatments?\",\"answer\":\"The review describes microbiome roles in modulating antitumor immunity and influencing response to chemotherapy, immunotherapy, and radiation therapy, including therapy resistance.\"},{\"question\":\"Why can’t pharmacogenomic biomarkers fully explain individual differences in drug response?\",\"answer\":\"Clinical evidence indicates pharmacogenomic markers only partially account for inter-individual variation, motivating additional biomarker research beyond genetics.\"},{\"question\":\"What barriers limit microbiome-based interventions in cancer therapy?\",\"answer\":\"Major challenges include standardization of methods, validation of findings, and effective clinical translation from research into routine practice.\"}]","Pharmacomicrobiomics in precision cancer therapy - bench to bedside | PDF",1790004238,66]